Molbio Diagnostics Limited Announced its Initial public offering (IPO) to open on Monday, August 10, 2026 Price Band fixed at ₹ 768 per equity share of face value ₹1 each to ₹ 807 per equity share of the face value of ₹1 each

Molbio 1 — L to R: Mr. Kaushal Shah, Managing Director and Head – Equity Capital Markets, Kotak Mahindra Capital Company Limited; Molbio Diagnostics Limited team — Mr. Indraneil Borkakoty, President – Corporate Strategy, M&A, Investor Relations; Mr. Shiva Sriram, President – Business Development; Mr. Sriram Natarajan, Executive Director & Chief Executive Officer; Dr. Chandrasekhar Nair, Executive Director & Chief Technology Officer; Mr. Manan Khokhani, Chief Financial Officer & President – Finance & Accounts, Molbio Diagnostics Limited; Mr. Shirish Chikalge, Senior Vice President and Head – Healthcare, IIFL Capital Services Limited; and Mr. Kushagr Mathur, Assistant Vice President – Equity Capital Markets, Motilal Oswal Investment Advisors Limited at the press conference to announce the IPO of Molbio Diagnostics Limited

Molbio 2 — L to R: Molbio Diagnostics Limited team — Mr. Indraneil Borkakoty, President – Corporate Strategy, M&A, Investor Relations; Mr. Shiva Sriram, President – Business Development; Mr. Sriram Natarajan, Executive Director & Chief Executive Officer; Dr. Chandrasekhar Nair, Executive Director & Chief Technology Officer; Mr. Manan Khokhani, Chief Financial Officer & President – Finance & Accounts, at the press conference to announce the IPO of Molbio Diagnostics Limited

Molbio 3 — L to R: Mr. Sriram Natarajan, Executive Director & Chief Executive Officer, Molbio Diagnostics Limited and Dr. Chandrasekhar Nair, Executive Director & Chief Technology Officer, Molbio Diagnostics Limited at the press conference to announce the IPO.

Molbio Diagnostics Limited: Initial public offering to open on Monday, August 10, 2026
Price Band fixed at ₹ 768 per equity share of face value ₹1 each to ₹ 807 per equity share of the face value of ₹1 each (“Equity Shares”) of Molbio Diagnostics Limited (the “Company”)
Anchor Investor Bidding Date – Friday, August 7, 2026
Bid /Offer Opening Date – Monday, August 10, 2026, and Bid/ Offer Closing Date – Wednesday, August 12, 2026
Bids can be made for a minimum of 18 Equity Shares of face value ₹1 and in multiples of 18 Equity Shares of face value ₹1 thereafter
Employee Reservation Portion aggregating up to ₹15 million, discount of ₹76 per Equity Share being offered to Eligible Employees
Red Herring Prospectus dated August 3, 2026 (“RHP”) link – https://www.molbiodiagnostics.com/wp-content/uploads/2026/08/Molbio-Diagnostics-Limited-Red-Herring-Prospectus.pdf

Mumbai, August 5, 2026 (GNI) : Molbio Diagnostics Limited (the “Company”) proposes to open an initial public offering of its equity shares of face value of ₹1 each (“Equity Shares” and such offering the “Offer”) on Monday, August 10, 2026. The Anchor Investor Bidding Date is one Working Day prior to Bid/Offer Opening Date, being Friday, August 7, 2026. The Bid/ Offer Closing Date is Wednesday, August 12, 2026*.
*UPI mandate end time and date shall be at 5:00 pm on the Bid/Offer Closing Date.

The Price Band of the Offer has been fixed from ₹ 768 per Equity Share of face value ₹1 each to ₹ 807 per Equity Share of face value ₹1 each. Bids can be made for a minimum of 18 Equity Shares of face value ₹1 each and multiples of 18 Equity Shares of face value ₹1 each thereafter.
The Offer comprises of a Fresh Issue of Equity Shares aggregating up to ₹2,000.00 million and an Offer for Sale of up to 91,66,000 Equity Shares by the Selling Shareholders.
The Offer for Sale includes up to 1,811,000 Equity Shares aggregating up to ₹ [●] million by Exxora Trading LLP (Promoter Selling Shareholder); up to 1,221,000 Equity Shares aggregating up to ₹ [●] million by Dr. Chandrasekhar Bhaskaran Nair (Promoter Selling Shareholder); up to 1,000,000 Equity Shares aggregating up to ₹ [●] million by India Business Excellence Fund III (Investor Selling Shareholder); and following Other Selling Shareholders – up to 1,125,000 Equity Shares aggregating up to ₹ [●] million by Gopalkrishna Mangalore Kini; up to 902,000 Equity Shares aggregating up to ₹ [●] million by J. Guru Dutt; up to 902,000 Equity Shares aggregating up to ₹ [●] million by Gopalakrishna Sampathgiri; up to 452,000 Equity Shares aggregating up to ₹ [●] million by Sangeetha M Kini; up to 451,000 Equity Shares aggregating up to ₹ [●] million by M.A. Usha Rani; up to 248,000 Equity Shares aggregating up to ₹ [●] million by M.A. Rohit; up to 226,000 Equity Shares aggregating up to ₹ [●] million by Shruthi G Kini; up to 202,000 Equity Shares aggregating up to ₹ [●] million by M.A. Sharath; up to 193,000 Equity Shares aggregating up to ₹ [●] million by Chewbacca Services Limited; up to 193,000 Equity Shares aggregating up to ₹ [●] million by Sujay Limited; up to 97,000 Equity Shares aggregating up to ₹ [●] million by Shaheeda Abdul Kader; up to 78,000 Equity Shares aggregating up to ₹ [●] million by Vivek Devaraj; up to 48,000 Equity Shares aggregating up to ₹ [●] million by Abdul Qadir Mohamed Theruvath and up to 17,000 Equity Shares aggregating up to ₹ [●] million by M Ganesh Kamath (collectively “Selling Shareholders”).

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957 (“SCRR”) read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”, and such portion, the “QIB Portion”), provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”), out of which 40% shall be available for allocation as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds, at or above the price at which allocation will be made to Anchor Investors (“Anchor Investor Allocation Price”) in accordance with the SEBI ICDR Regulations. Any under-subscription in the portion amounting to 6.67% reserved for Life Insurance Companies and Pension Funds may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (the “Net QIB Portion”). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to all QIBs.
Further, not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders (out of which one-third of the portion available to Non-Institutional Bidders shall be reserved for Bidders with an application size of more than ₹ 0.20 million and up to ₹ 1.00 million and two-thirds shall be reserved for Bidders with an application size of more than ₹ 1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to Bidders in the other sub-category) and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price.
Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.
All Bidders, other than Anchor Investors, are required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA Account (as defined hereinafter) and UPI ID in case of UPI Bidders (as defined hereinafter), as applicable, pursuant to which their corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“SCSBs”) or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process.
The Equity Shares of the Company are proposed to be listed on BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”) (BSE and NSE together, the “Stock Exchanges”).
Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited are the Book Running Lead Managers (“BRLMs”) to the Offer.

All capitalized terms used but not defined herein shall have the meaning assigned to them in the Red Herring Prospectus.

The RHP shall be available on the website of SEBI at www.sebi.gov.in, and is available on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.molbiodiagnostics.com and the websites of the BRLMs, i.e. Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited), Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited at https://investmentbank.kotak.com, www.iiflcapital.com, www.jefferies.com and www.motilaloswal.com, respectively.ends GNI